Number of the records: 1
TRAIL (Apo2L) supresses growth of primary human leukemia and myelodysplasia progenitors
- 1.0191506 - UMG-J 20023088 RIV US eng J - Journal Article
Plášilová, M. - Živná, J. - Jelínek, J. - Neuwirtová, R. - Čermák, J. - Nečas, E. - Anděra, Ladislav - Stopka, T.
TRAIL (Apo2L) supresses growth of primary human leukemia and myelodysplasia progenitors.
Leukemia. Roč. 16, č. 1 (2002), s. 67-73. ISSN 0887-6924. E-ISSN 1476-5551
R&D Projects: GA AV ČR IAA5052001; GA ČR GA301/99/0350
Keywords : TRAIL * leukemia * myelodysplasia
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 4.693, year: 2002
Recombinant His-TRAIL reduced the number of myeloid colonies from patients with myeloid leukemia and myelodysplstic syndromes. TRAIL did not affect normal human hematopoiesis but suppressed the growth of early primary leukemia progenitors.
Permanent Link: http://hdl.handle.net/11104/0087257
Number of the records: 1